http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0522226-B1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97a7b5e6cb1e38a210c1efd7fb78d16a |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
filingDate | 1991-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 1997-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66b07938e07728113b83149a8ed7c569 |
publicationDate | 1997-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-0522226-B1 |
titleOfInvention | Eyedrop solution for the treatment of ocular hypertension containing ketauserin |
abstract | Eyedrop solution for the treatment of ocular hypertension characterized by the fact of consisting essentially of the combination of the following components expressed in percent by weight: from 0.01 to 2.0% of at least one hydrosoluble salt of ketanserin, for example ketanserin tartrate; optionally, from 0.01 to 10% of a substance that may stabilize the lacrimal film, selected preferably from the group comprising hydroxymethylcellulose, polyacrylic acid, propylenglycol, anhydrous dextrose and their combinations; optionally, from 0.001 to 0.01% of a preservative, for example benzalkonium chloride; optionally, a buffer system for maintaining the pH between the range 4.5 - 6.0, for example 0.1 - 1.0% of monopotassium phosphate and 0.1 - 1.5% of disodium phosphate; optionally, a colorimetric indicator that is biocompatible and pharmaceutically acceptable for revealing departures in the pH from the range 4.5 - 6.0; optionally, a solution that is isotonic with the osmotic pressure of the lacrimal fluid; optionally, at least one substance selected from the group comprising beta blockers, pilocarpine, alpha blockers, inhibitors of carbonic anhydrase, inhibitors of angiotensin converting enzyme and their combinations, the balance up to 100% being water. i |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7005448-B2 |
priorityDate | 1991-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.